Meronem is generally well-tolerated. Adverse events rarely lead to cessation of treatment. Serious adverse events are rare.
The adverse reactions are described according to the following frequencies: Common (≥1% and <10%): General Disorders and Administration Site Conditions: Inflammation, thrombophlebitis, pain.
Blood and Lymphatic System Disorders1: Thrombocythaemia.
Gastrointestinal Disorders: Nausea, vomiting, diarrhoea.
Hepatobiliary Disorders: Increased serum transaminases, bilirubin, alkaline phosphatase, lactic dehydrogenase.
Uncommon (≥0.1% and <1%): Blood and Lymphatic System Disorders: Eosinophilia, thrombocytopenia.
Skin and Subcutaneous Tissue Disorders: Rash, urticaria, pruritus.
Nervous System Disorders: Headache, paraesthesiae.
Rare (≥0.01% and <0.1%): General and Administration Site Dosorders: Oral and vaginal candidiasis.
Blood and Lympatic System Disorders: Leucopenia, neutropenia, agranulocytosis.
Nervous System Disorders: Convulsions2.
Very Rare (<0.01%): Blood and Lymphatic System Disorders: Haemolytic anaemia.
Immune System Disorders: Angioedema, manifestations of anaphylaxis.
Skin and Subcutaneous Tissue Disorders: Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis.
Gastrointestinal Disorders: Pseudomembranous colitis.
Note: 1A positive direct or indirect Coombs' test may develop in some subjects; there have been reports of reduction in partial thromboplastin time. 2Convulsions have been observed in temporal association with the administration of Meronem; a causal relationship with Meronem has not been established.